Details

Autor(en) / Beteiligte

• Garfall, Alfred L
• Maus, Marcela V
• Hwang, Wei-Ting
• Lacey, Simon F
• Mahnke, Yolanda D
• Melenhorst, J. Joseph
• Zheng, Zhaohui
• Vogl, Dan T
• Cohen, Adam D
• Weiss, Brendan M
• Dengel, Karen
• Kerr, Naseem D.S
• Bagg, Adam
• Levine, Bruce L
• June, Carl H
• Stadtmauer, Edward A

Titel

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

Ist Teil von

• The New England journal of medicine, 2015-09, Vol.373 (11), p.1040-1047

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Antitumor effects were noted in a heavily pretreated patient with CD19-negative myeloma who received CD19-specific chimeric antigen receptor T cells. The mechanism of the antitumor effects is unclear. Transduction of autologous T cells to express CD19-specific chimeric antigen receptors is a promising immunotherapeutic approach for the treatment of B-cell cancers. 1 We previously reported sustained regression of refractory chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia 2 – 5 after infusion of CTL019 cells, which consist of autologous T cells expressing a CD3-zeta/CD137–based anti-CD19 chimeric antigen receptor from a lentiviral vector. Multiple myeloma is a B-lineage cancer that is reported to express CD19 infrequently 6 ; hence, CD19 is not generally considered a valid immunotherapeutic target in multiple myeloma. Several reports, however, have suggested that a minor component of the multiple myeloma . . .